Stephen L. Rawlings

Array ( [id] => 7650888 [patent_doc_number] => 20110300157 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-12-08 [patent_title] => 'METALLOPROTEINASE 9 AND METALLOPROTEINASE 2 BINDING PROTEINS' [patent_app_type] => utility [patent_app_number] => 13/195710 [patent_app_country] => US [patent_app_date] => 2011-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 84773 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0300/20110300157.pdf [firstpage_image] =>[orig_patent_app_number] => 13195710 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8293968 [patent_doc_number] => 08221749 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-07-17 [patent_title] => 'Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof' [patent_app_type] => utility [patent_app_number] => 13/194854 [patent_app_country] => US [patent_app_date] => 2011-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 41795 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13194854 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7560855 [patent_doc_number] => 20110274687 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-11-10 [patent_title] => 'METHODS OF TREATING TSLP-RELATED INFLAMMATORY DISORDERS' [patent_app_type] => utility [patent_app_number] => 13/185021 [patent_app_country] => US [patent_app_date] => 2011-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 33200 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0274/20110274687.pdf [firstpage_image] =>[orig_patent_app_number] => 13185021 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7731527 [patent_doc_number] => 20120014947 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-01-19 [patent_title] => 'METHODS AND COMPOSITIONS TO REDUCE LIVER DAMAGE ASSOCIATED WITH CONDITIONS OR THERAPIES THAT AFFECT THE IMMUNE SYSTEM' [patent_app_type] => utility [patent_app_number] => 13/183617 [patent_app_country] => US [patent_app_date] => 2011-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 8765 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0014/20120014947.pdf [firstpage_image] =>[orig_patent_app_number] => 13183617 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8027859 [patent_doc_number] => 08143011 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-03-27 [patent_title] => 'MAGE-C2 antigenic peptides and uses thereof' [patent_app_type] => utility [patent_app_number] => 13/182037 [patent_app_country] => US [patent_app_date] => 2011-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 24 [patent_no_of_words] => 19712 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/143/08143011.pdf [firstpage_image] =>[orig_patent_app_number] => 13182037 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7567939 [patent_doc_number] => 20110288002 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-11-24 [patent_title] => 'NOVEL BAG PROTEINS AND NUCLEIC ACID MOLECULES ENCODING THEM' [patent_app_type] => utility [patent_app_number] => 13/180232 [patent_app_country] => US [patent_app_date] => 2011-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 39 [patent_no_of_words] => 10924 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0288/20110288002.pdf [firstpage_image] =>[orig_patent_app_number] => 13180232 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7710291 [patent_doc_number] => 20120003251 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-01-05 [patent_title] => 'ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES' [patent_app_type] => utility [patent_app_number] => 13/173692 [patent_app_country] => US [patent_app_date] => 2011-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 27396 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13173692 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7587527 [patent_doc_number] => 20110282037 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-11-17 [patent_title] => 'ANTIBODY PREPARATION' [patent_app_type] => utility [patent_app_number] => 13/162755 [patent_app_country] => US [patent_app_date] => 2011-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 7571 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0282/20110282037.pdf [firstpage_image] =>[orig_patent_app_number] => 13162755 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7555109 [patent_doc_number] => 08067009 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2011-11-29 [patent_title] => 'Metalloproteinase oligopeptides and their therapeutic use' [patent_app_type] => utility [patent_app_number] => 13/159941 [patent_app_country] => US [patent_app_date] => 2011-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 5696 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/067/08067009.pdf [firstpage_image] =>[orig_patent_app_number] => 13159941 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9523851 [patent_doc_number] => 08748114 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-06-10 [patent_title] => 'ZAP-70 expression as a marker for chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL)' [patent_app_type] => utility [patent_app_number] => 13/155198 [patent_app_country] => US [patent_app_date] => 2011-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 8 [patent_no_of_words] => 24656 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13155198 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8209009 [patent_doc_number] => 20120128661 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-05-24 [patent_title] => 'POLYNUCLEOTIDE AND POLYPEPTIDE SEQUENCES INVOLVED IN CANCER' [patent_app_type] => utility [patent_app_number] => 13/152209 [patent_app_country] => US [patent_app_date] => 2011-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 37252 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0128/20120128661.pdf [firstpage_image] =>[orig_patent_app_number] => 13152209 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7488427 [patent_doc_number] => 20110251376 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-10-13 [patent_title] => 'Mammalian Tumor Susceptibility Genes and their Uses' [patent_app_type] => utility [patent_app_number] => 13/116911 [patent_app_country] => US [patent_app_date] => 2011-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 13090 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0251/20110251376.pdf [firstpage_image] =>[orig_patent_app_number] => 13116911 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8909623 [patent_doc_number] => 08481688 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-07-09 [patent_title] => 'Anti-FGFR2 antibodies' [patent_app_type] => utility [patent_app_number] => 13/105521 [patent_app_country] => US [patent_app_date] => 2011-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 15497 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13105521 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7509779 [patent_doc_number] => 20110256056 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-10-20 [patent_title] => 'Monoclonal Antibodies Against HER2 Antigens, and Uses Therefor' [patent_app_type] => utility [patent_app_number] => 13/087351 [patent_app_country] => US [patent_app_date] => 2011-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 18835 [patent_no_of_claims] => 50 [patent_no_of_ind_claims] => 18 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0256/20110256056.pdf [firstpage_image] =>[orig_patent_app_number] => 13087351 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8909624 [patent_doc_number] => 08481687 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-07-09 [patent_title] => 'Anti-ErbB3 antibodies' [patent_app_type] => utility [patent_app_number] => 13/082852 [patent_app_country] => US [patent_app_date] => 2011-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 30 [patent_no_of_words] => 33271 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13082852 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7663961 [patent_doc_number] => 20110313230 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-12-22 [patent_title] => 'SPECIFIC BINDING PROTEINS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/078764 [patent_app_country] => US [patent_app_date] => 2011-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 162 [patent_figures_cnt] => 162 [patent_no_of_words] => 85871 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13078764 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9827936 [patent_doc_number] => 08937164 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-01-20 [patent_title] => 'Biological materials related to CXCR7' [patent_app_type] => utility [patent_app_number] => 13/073044 [patent_app_country] => US [patent_app_date] => 2011-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 41206 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13073044 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13182197 [patent_doc_number] => 10106600 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-23 [patent_title] => Bispecific antibodies [patent_app_type] => utility [patent_app_number] => 13/070582 [patent_app_country] => US [patent_app_date] => 2011-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 22451 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13070582 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7499482 [patent_doc_number] => 20110262454 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-10-27 [patent_title] => 'NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER' [patent_app_type] => utility [patent_app_number] => 13/069705 [patent_app_country] => US [patent_app_date] => 2011-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 33057 [patent_no_of_claims] => 79 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0262/20110262454.pdf [firstpage_image] =>[orig_patent_app_number] => 13069705 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10534908 [patent_doc_number] => 09260529 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-02-16 [patent_title] => 'Molecules that bind CD180, compositions and methods of use' [patent_app_type] => utility [patent_app_number] => 13/034144 [patent_app_country] => US [patent_app_date] => 2011-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 16 [patent_no_of_words] => 18637 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13034144 [rel_patent_id] =>[rel_patent_doc_number] =>)